bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from AFDN Deficiency Promotes Liver Tropism of Metastatic Colorectal Cancer
Authors: Liao Shaoxia , Deng Jingwen , Deng Mengli , Chen Chaoyi , Han Fengyan , Ye Kehong , Wu Chenxia , Pan Lvyuan , Lai Maode , Tang Zhe , Zhang Honghe
Published: October 2024

Abstract
Liver metastasis is a major cause of morbidity and mortality in patients with colorectal cancer. A better understanding of the biological mechanisms underlying liver tropism and metastasis in colorectal cancer could help to identify improved prevention and treatment strategies. In this study, we performed genome-wide CRISPR loss-of-function screening in a mouse colorectal cancer model and identified deficiency of AFDN, a protein involved in establishing and maintaining cell–cell contacts, as a driver of liver metastasis. Elevated AFDN expression was correlated with prolonged survival in patients with colorectal cancer. AFDN-deficient colorectal cancer cells preferentially metastasized to the liver but not in the lungs. AFDN loss in colorectal cancer cells at the primary site promoted cancer cell migration and invasion by disrupting tight intercellular junctions. Additionally, CXCR4 expression was increased in AFDN-deficient colorectal cancer cells via the JAK-STAT signaling pathway, which reduced the motility of AFDN-deficient colorectal cancer cells and facilitated their colonization of the liver. Collectively, these data shed light on the mechanism by which AFDN deficiency promotes liver tropism in metastatic colorectal cancer.

Significance: A CRISPR screen reveals AFDN loss as a mediator of liver tropism in colorectal cancer metastasis by decreasing tight junctions in the primary tumor and increasing interactions between cancer cells and hepatocytes.
Supplementary Table S3 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

List of up-regulated genes identified by differential gene expression when comparing NSCLC with KEAP1-NFE2L2 VUS (OncoKB) versus wild-type samples in the TCGA NSCLC study.
Supplementary Figure S4 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 4. KEAPness and pathway-level signatures (PROGENy) in NSCLC (TCGA).
Supplementary Figure S3 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 3. KEAPness in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) in the TCGA
Supplementary Figure S22 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 22. KEAPness transcriptional heterogeneity in relation to histology in the TRACERx 421 cohort.
Supplementary Figure S21 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 21. Impact of simplified KEAPness gene expression models in the pooled SU2C/OAK/POPLAR cohort
Supplementary Figure S20 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 20. Relationship between KEAPness and STK11 mutations in the pooled SU2C/OAK/POPLAR cohort
Supplementary Figure S18 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 18. KEAPness and the 29 tumor microenvironment (TIME)-related signatures in the pooled SU2C/OAK/POPLAR cohort (immunotherapy-treated population).
Supplementary Figure S17 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 17. Relationship between the KEAPness dominant phenotype and two IFN-γ-related signatures in the whole immunotherapy-treated population (SU2C/OAK/POPLAR).
Supplementary Figure S12 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Authors: Scalera Stefano , Ricciuti Biagio , Marinelli Daniele , Mazzotta Marco , Cipriani Laura , Bon Giulia , Schiavoni Giulia , Terrenato Irene , Di Federico Alessandro , Alessi Joao V. , Fanciulli Maurizio , Ciuffreda Ludovica , De Nicola Francesca , Goeman Frauke , Caravagna Giulio , Santini Daniele , De Maria Ruggero , Cappuzzo Federico , Ciliberto Gennaro , Jamal-Hanjani Mariam , Awad Mark M. , McGranahan Nicholas , Maugeri-Saccà Marcello
Published: October 2024

Supplementary Figure 12. PD-L1 tumor proportion score (TPS) in the SU2C identification cohort.
Supplemental Figure S3 from Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
Authors: Kazandjian Dickran , Diamond Benjamin , Papadimitriou Marios , Hill Elizabeth , Sklavenitis-Pistofidis Romanos , Ziccheddu Bachisio , Blaney Patrick , Chojnacka Monika , Durante Michael , Maclachlan Kylee , Young Ryan , Usmani Saad , Davies Faith , Getz Gad , Ghobrial Irene , Korde Neha , Morgan Gareth , Maura Francesco , Landgren Ola
Published: October 2024

Supplemental Figure S3. Cumulative Copy Number Profiles for treated HR-SMM.
Supplementary Figure S1 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance
Authors: Bugno Jason , Wang Liangliang , Yu Xianbin , Cao Xuezhi , Wang Jiaai , Huang Xiaona , Yang Kaiting , Piffko Andras , Chen Katherine , Luo Stephen Y. , Naccasha Emile , Hou Yuzhu , Fu Sherry , He Chuan , Fu Yang-xin , Liang Hua L. , Weichselbaum Ralph R.
Published: October 2024

Supplementary Figure S1. CCL22-expressing cDC are associated with worse survival in cancer patients
Supplementary Table S3 from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade
Authors: Luthria Karan , Shah Parin , Caldwell Blake , Melms Johannes C. , Abuzaid Sinan , Jakubikova Viktoria , Brodtman D. Zack , Bose Sminu , Amin Amit Dipak , Ho Patricia , Biermann Jana , Tagore Somnath , Ingham Matthew , Schwartz Gary K. , Izar Benjamin
Published: October 2024

Supplemental Table 3: T-cell receptor sequences and clonality.
Supplementary Table S4 from Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim
Authors: Andersson Axel , Escriva Conde Maria , Surova Olga , Vermeulen Peter , Wählby Carolina , Nilsson Mats , Nyström Hanna
Published: October 2024

Supplementary Table S4. P-values for different neighborhood enrichment tests performed within the rim region in the 10 desmoplastic samples.
Supplementary Table S1 from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade
Authors: Luthria Karan , Shah Parin , Caldwell Blake , Melms Johannes C. , Abuzaid Sinan , Jakubikova Viktoria , Brodtman D. Zack , Bose Sminu , Amin Amit Dipak , Ho Patricia , Biermann Jana , Tagore Somnath , Ingham Matthew , Schwartz Gary K. , Izar Benjamin
Published: October 2024

Supplemental Table 1: Assays performed and basic quality metrics of included samples.
Supplementary Table S3 from Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim
Authors: Andersson Axel , Escriva Conde Maria , Surova Olga , Vermeulen Peter , Wählby Carolina , Nilsson Mats , Nyström Hanna
Published: October 2024

Supplementary Table S3. Detection oligo (DO) sequence for each fluorophore.
Supplementary Table S1 from Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim
Authors: Andersson Axel , Escriva Conde Maria , Surova Olga , Vermeulen Peter , Wählby Carolina , Nilsson Mats , Nyström Hanna
Published: October 2024

Supplementary Table S1. Genes included in the panel together with their corresponding Entrez ID.
Supplementary Figure S4 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Authors: Sundby R. Taylor , Szymanski Jeffrey J. , Pan Alexander C. , Jones Paul A. , Mahmood Sana Z. , Reid Olivia H. , Srihari Divya , Armstrong Amy E. , Chamberlain Stacey , Burgic Sanita , Weekley Kara , Murray Béga , Patel Sneh , Qaium Faridi , Lucas Andrea N. , Fagan Margaret , Dufek Anne , Meyer Christian F. , Collins Natalie B. , Pratilas Christine A. , Dombi Eva , Gross Andrea M. , Kim AeRang , Chrisinger John S.A. , Dehner Carina A. , Widemann Brigitte C. , Hirbe Angela C. , Chaudhuri Aadel A. , Shern Jack F.
Published: October 2024

Supplemental Figure 4. 4-mer end motifs across F-profiles. Comprehensive view of the distribution and prevalence of each possible 4-mer end motif within each of the six distinct F-profiles derived from non-negative matrix factorization (NMF) (Methods). The analysis highlights distinct end motif compositions and non-random distribution of end nucleotides across the F-profiles.
Supplementary Figure S2 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Authors: Sundby R. Taylor , Szymanski Jeffrey J. , Pan Alexander C. , Jones Paul A. , Mahmood Sana Z. , Reid Olivia H. , Srihari Divya , Armstrong Amy E. , Chamberlain Stacey , Burgic Sanita , Weekley Kara , Murray Béga , Patel Sneh , Qaium Faridi , Lucas Andrea N. , Fagan Margaret , Dufek Anne , Meyer Christian F. , Collins Natalie B. , Pratilas Christine A. , Dombi Eva , Gross Andrea M. , Kim AeRang , Chrisinger John S.A. , Dehner Carina A. , Widemann Brigitte C. , Hirbe Angela C. , Chaudhuri Aadel A. , Shern Jack F.
Published: October 2024

Supplemental Figure 2. Diminishing improvements in accuracy with deeper sequencing. MPNST samples sequenced to ∼25x were downsampled in five iterations per goal coverage (Methods). Size selected, copy number derived tumor fraction variability was noted between iterations less than or equal to 3x with statistically significant differences in tumor fraction (*, Welch’s T-test) between 25x coverage and 3x or below sequencing depths. No statistical difference (ns) was noted in tumor fraction between 25x coverage and sequencing depths greater than or equal to 6x.
Supplemental Table 5 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Authors: Hussain Maha , Kocherginsky Masha , Agarwal Neeraj , Adra Nabil , Zhang Jingsong , Paller Channing J. , Picus Joel , Reichert Zachery R. , Szmulewitz Russell Z. , Tagawa Scott T. , Kuzel Timothy M. , Bazzi Latifa A. , Daignault-Newton Stephanie , Whang Young E. , Dreicer Robert , Stephenson Ryan D. , Rettig Matthew B. , Shevrin Daniel , Gerke Travis , Chinnaiyan Arul M. , Antonarakis Emmanuel S.
Published: October 2024

Supplemental Table 5. Treatment-Related AEs in Exploratory Arms.
Supplemental Table 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Authors: Hussain Maha , Kocherginsky Masha , Agarwal Neeraj , Adra Nabil , Zhang Jingsong , Paller Channing J. , Picus Joel , Reichert Zachery R. , Szmulewitz Russell Z. , Tagawa Scott T. , Kuzel Timothy M. , Bazzi Latifa A. , Daignault-Newton Stephanie , Whang Young E. , Dreicer Robert , Stephenson Ryan D. , Rettig Matthew B. , Shevrin Daniel , Gerke Travis , Chinnaiyan Arul M. , Antonarakis Emmanuel S.
Published: October 2024

Supplemental Table 2. SAEs per arm.
Supplementary Table S2 from Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Authors: Lizardo Michael M. , Hughes Christopher , Huang Yue Z. , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Shaool Sol Snir , Renner Annalena F. , Burwag Farez , Sayles Leanne C. , Lee Alex G. , Sweet-Cordero Alejandro , Sorensen Poul H.
Published: October 2024

Supplemental Table 2. IC50 values of CR-1-31B in an expanded panel of metastatic OS models.
Supplementary Figure S6 from Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Authors: Lizardo Michael M. , Hughes Christopher , Huang Yue Z. , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Shaool Sol Snir , Renner Annalena F. , Burwag Farez , Sayles Leanne C. , Lee Alex G. , Sweet-Cordero Alejandro , Sorensen Poul H.
Published: October 2024

Fig. S6. CR-1-31B sensitizes OS cells to oxidative stress
Supplementary Figure S1 from Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Authors: Lizardo Michael M. , Hughes Christopher , Huang Yue Z. , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Shaool Sol Snir , Renner Annalena F. , Burwag Farez , Sayles Leanne C. , Lee Alex G. , Sweet-Cordero Alejandro , Sorensen Poul H.
Published: October 2024

Fig. S1. Single agent activity of CR-1-31B in osteosarcoma (OS) cells
Supplementary Table S5 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Authors: Monson Kelsey R. , Ferguson Robert , Handzlik Joanna E. , Xiong Jiahan , Dagayev Sasha , Morales Leah , Chat Vylyny , Bunis Anabelle , Sreenivasaiah Chaitra , Dolfi Sonia , Tenney Daniel J. , Shao Yongzhao , Osman Iman , Weber Jeffrey S. , Kirchhoff Tomas
Published: October 2024

Supplementary Table S5. Gene signature for COMBO CD4+ DEGs in MAPK8 and MAPK14 pathways, High vs Low Toxicity.
Supplementary Figure S7 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Authors: Monson Kelsey R. , Ferguson Robert , Handzlik Joanna E. , Xiong Jiahan , Dagayev Sasha , Morales Leah , Chat Vylyny , Bunis Anabelle , Sreenivasaiah Chaitra , Dolfi Sonia , Tenney Daniel J. , Shao Yongzhao , Osman Iman , Weber Jeffrey S. , Kirchhoff Tomas
Published: October 2024

Supplementary Figure S7. Waterfall plot for logistic regression model predicting severe (grade 3-5) irAEs using 24-gene SYK GEP.
Supplementary Data 1 from Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia
Authors: Marrero Richard J. , Wu Huiyun , Cao Xueyuan , Parcha Phani Krishna , Elsayed Abdelrahman H. , Inaba Hiroto , Kuo Dennis John , Degar Barbara A. , Heym Kenneth , Taub Jeffrey W. , Lacayo Norman , Pui Ching-Hon , Ribeiro Raul C. , Rubnitz Jeffrey E. , Pounds Stanley B. , Lamba Jatinder K.
Published: October 2024

Supplementary Tables and Figures
Supplementary Table 5 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
Authors: Nakamura Yoshiaki , Tsukada Yuichiro , Matsuhashi Nobuhisa , Murano Tatsuro , Shiozawa Manabu , Takahashi Yusuke , Oki Eiji , Goto Masahiro , Kagawa Yoshinori , Kanazawa Akiyoshi , Ohta Takashi , Ouchi Akira , Bando Hideaki , Uchigata Hiroshi , Notake Chiemi , Ikematsu Hiroaki , Yoshino Takayuki
Published: October 2024

Supplementary Table 5. Risk of recurrence based on ctDNA detection 28 days post-surgery by pathologic stage. Tables to accompany Supplementary Figures 7A-D.
Supplementary Table 2 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
Authors: Nakamura Yoshiaki , Tsukada Yuichiro , Matsuhashi Nobuhisa , Murano Tatsuro , Shiozawa Manabu , Takahashi Yusuke , Oki Eiji , Goto Masahiro , Kagawa Yoshinori , Kanazawa Akiyoshi , Ohta Takashi , Ouchi Akira , Bando Hideaki , Uchigata Hiroshi , Notake Chiemi , Ikematsu Hiroaki , Yoshino Takayuki
Published: October 2024

Supplementary Table 2. Clinical and Testing Data on the Eligible Enrolled Cohort.
Supplementary Figure 6 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
Authors: Nakamura Yoshiaki , Tsukada Yuichiro , Matsuhashi Nobuhisa , Murano Tatsuro , Shiozawa Manabu , Takahashi Yusuke , Oki Eiji , Goto Masahiro , Kagawa Yoshinori , Kanazawa Akiyoshi , Ohta Takashi , Ouchi Akira , Bando Hideaki , Uchigata Hiroshi , Notake Chiemi , Ikematsu Hiroaki , Yoshino Takayuki
Published: October 2024

Supplementary Figure 6. Patterns of recurrence in the Longitudinal Analysis population.
Supplementary Table S4 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Authors: Zeverijn Laurien J. , Geurts Birgit S. , Battaglia Thomas W. , van Berge Henegouwen Jade M. , de Wit Gijs F. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , Roepman Paul , de Leng Wendy W.J. , Jansen Anne M.L. , Chalabi Myriam , van Herpen Carla M.L. , Devriese Lot A. , Erdkamp Frans L.G. , Labots Mariette , de Jonge Maja J.A. , Kerver Emile D. , Bins Adriaan D. , Leek Lindsay V.M. , Notohardjo Jessica C.L. , van den Eertwegh Alfonsus J.M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , van de Haar Joris , Voest Emile E.
Published: October 2024

Supplementary Table S4. Evaluated immune marker gene sets.
Supplementary Table S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Authors: Zeverijn Laurien J. , Geurts Birgit S. , Battaglia Thomas W. , van Berge Henegouwen Jade M. , de Wit Gijs F. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , Roepman Paul , de Leng Wendy W.J. , Jansen Anne M.L. , Chalabi Myriam , van Herpen Carla M.L. , Devriese Lot A. , Erdkamp Frans L.G. , Labots Mariette , de Jonge Maja J.A. , Kerver Emile D. , Bins Adriaan D. , Leek Lindsay V.M. , Notohardjo Jessica C.L. , van den Eertwegh Alfonsus J.M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , van de Haar Joris , Voest Emile E.
Published: October 2024

Supplementary Table S1. Representativeness of study participants.
Supplementary Table S3 from FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation
Authors: Pamuk Gulsum E. , Chow Edwin C.Y. , Ionan Alexei C. , Chen Haiyan , Lee Shwu-Luan , Hsu Vicky , Grimstein Manuela , Zheng Nan , Sun Jielin , Charlab Rosane , Gehrke Brenda J. , Vallejo Jonathon , Ehrlich Lori A. , de Claro R. Angelo , Theoret Marc R.
Published: October 2024

Select laboratory abnormalities (≥ 10%) that worsened from baseline in patients with Ph + CML in CP, previously treated with two or more tyrosine kinase inhibitors in ASCEMBL
Supplementary Table S2 from FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation
Authors: Pamuk Gulsum E. , Chow Edwin C.Y. , Ionan Alexei C. , Chen Haiyan , Lee Shwu-Luan , Hsu Vicky , Grimstein Manuela , Zheng Nan , Sun Jielin , Charlab Rosane , Gehrke Brenda J. , Vallejo Jonathon , Ehrlich Lori A. , de Claro R. Angelo , Theoret Marc R.
Published: October 2024

The list of preferred terms included in grouped terms used for safety analysis in ASCEMBL
Supplementary Table S5 from Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy
Authors: González-Medina Alberto , Vila-Casadesús Maria , Gomez-Rey Marina , Fabregat-Franco Carles , Sierra Alexandre , Tian Tian V. , Castet Florian , Castillo Gloria , Matito Judit , Martinez Paola , Miquel Josep M. , Nuciforo Paolo , Pérez-López Raquel , Macarulla Teresa , Vivancos Ana
Published: October 2024

Supplementary Table S5. Co-occurring alterations.
Supplementary Figure S7 from Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy
Authors: González-Medina Alberto , Vila-Casadesús Maria , Gomez-Rey Marina , Fabregat-Franco Carles , Sierra Alexandre , Tian Tian V. , Castet Florian , Castillo Gloria , Matito Judit , Martinez Paola , Miquel Josep M. , Nuciforo Paolo , Pérez-López Raquel , Macarulla Teresa , Vivancos Ana
Published: October 2024

Supplementary Figure S7. Blind testing of VHIO-iCCA panel in 30 patients, analyzed prospectively.
Table 1 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Authors: Bardia Aditya , Cortés Javier , Bidard François-Clément , Neven Patrick , Garcia-Sáenz José , Aftimos Phillipe , O’Shaughnessy Joyce , Lu Janice , Tonini Giulia , Scartoni Simona , Paoli Alessandro , Binaschi Monica , Wasserman Tomer , Kaklamani Virginia
Published: October 2024

Baseline characteristics in patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months.
Figure 3 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Authors: Bardia Aditya , Cortés Javier , Bidard François-Clément , Neven Patrick , Garcia-Sáenz José , Aftimos Phillipe , O’Shaughnessy Joyce , Lu Janice , Tonini Giulia , Scartoni Simona , Paoli Alessandro , Binaschi Monica , Wasserman Tomer , Kaklamani Virginia
Published: October 2024

PFS according to mutation and molecular expression subgroups. Kaplan–Meier estimates of PFS in patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of (A) PIK3CA-mut (n = 62; 39%); (B) PIK3CA wild-type (n = 97; 61%); (C) TP53-mut (n = 61; 38%); (D) TP53 wild-type (n = 97; 61%); (E) HER2-low expression (n = 77; 48%); (F) HER2-zero expression (n = 69; 43%); (G) ESR1D538G-mutated tumors (n = 97; 61%); or (H) ESR1Y537S/N-mutated tumors (n = 92; 58%). aIncludes the following PIK3CA-mut: E545K, H1047R, and E542K among others. bData not available for all patients. cHER2-low expression defined as IHC score of 1+ or 2+ with no amplification by ISH.
Data from Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
Authors: Kazandjian Dickran , Diamond Benjamin , Papadimitriou Marios , Hill Elizabeth , Sklavenitis-Pistofidis Romanos , Ziccheddu Bachisio , Blaney Patrick , Chojnacka Monika , Durante Michael , Maclachlan Kylee , Young Ryan , Usmani Saad , Davies Faith , Getz Gad , Ghobrial Irene , Korde Neha , Morgan Gareth , Maura Francesco , Landgren Ola
Published: October 2024

AbstractPurpose:
Early intervention for high-risk smoldering multiple myeloma (HR-SMM) achieves deep and prolonged responses. It is unclear if beneficial outcomes are due to the treatment of less complex, susceptible disease or inaccuracy in clinical definition of cases entered.
Experimental Design:
In this study, we interrogated whole-genome and whole-exome sequencing for 54 patients across two HR-SMM interventional studies (NCT01572480 and NCT02279394).
Results:
We reveal that the genomic landscape of treated HR-SMM is generally simple as compared with newly diagnosed multiple myeloma counterparts with less inactivation of tumor suppressor genes, RAS pathway mutations, MYC disruption, and APOBEC contribution. The absence of these events parallels that of indolent precursor conditions, possibly explaining overall excellent outcomes. However, some patients harboring genomic complexity fail to sustain response and experience resistant, progressive disease. Overall, clinical risk scores do not effectively discriminate between genomically indolent and aggressive disease.
Conclusions:
Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy.

See related commentary by Weinhold and Rasche, p. 4263
Data from Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Authors: Lizardo Michael M. , Hughes Christopher , Huang Yue Z. , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Shaool Sol Snir , Renner Annalena F. , Burwag Farez , Sayles Leanne C. , Lee Alex G. , Sweet-Cordero Alejandro , Sorensen Poul H.
Published: October 2024

AbstractPurpose:
Effective therapies for metastatic osteosarcoma (OS) remain a critical unmet need. Targeting mRNA translation in metastatic OS offers a promising option, as selective translation drives the synthesis of cytoprotective proteins under harsh microenvironmental conditions to facilitate metastatic competence.
Experimental Design:
We assessed the expression levels of eukaryotic translation factors in OS, revealing the high expression of the eukaryotic initiation factor 4A1 (EIF4A1). Using a panel of metastatic OS cell lines and patient-derived xenograft (PDX) models, EIF4A1 inhibitors were evaluated for their ability to block proliferation and reduce survival under oxidative stress, mimicking harsh conditions of the lung microenvironment. Inhibitors were also evaluated for their antimetastatic activity using the ex vivo pulmonary metastasis assay and in vivo metastasis models. Proteomics was performed to catalog which cytoprotective proteins or pathways were affected by EIF4A1 inhibition.
Results:
CR-1-31B, a rocaglate-based EIF4A1 inhibitor, exhibited nanomolar cytotoxicity against all metastatic OS models tested. CR-1-31B exacerbated oxidative stress and apoptosis when OS cells were co-treated with tert-butylhydroquinone, a chemical oxidative stress inducer. CR-1-31B potently inhibited OS growth in the pulmonary metastasis assay model and in experimental and spontaneous models of OS lung metastasis. Proteomic analysis revealed that tert-butylhydroquinone–mediated upregulation of the NRF2 antioxidant factor was blocked by co-treatment with CR-1-31B. Genetic inactivation of NRF2 phenocopied the antimetastatic activity of CR-1-31B. Finally, the clinical-grade EIF4A1 phase-1-to-2 inhibitor, zotatifin, similarly blocked NRF2 synthesis and the OS metastatic phenotype.
Conclusions:
Collectively, our data reveal that pharmacologic targeting of EIF4A1 is highly effective in blocking OS metastasis by blunting the NRF2 antioxidant response.
Data from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
Authors: Nakamura Yoshiaki , Tsukada Yuichiro , Matsuhashi Nobuhisa , Murano Tatsuro , Shiozawa Manabu , Takahashi Yusuke , Oki Eiji , Goto Masahiro , Kagawa Yoshinori , Kanazawa Akiyoshi , Ohta Takashi , Ouchi Akira , Bando Hideaki , Uchigata Hiroshi , Notake Chiemi , Ikematsu Hiroaki , Yoshino Takayuki
Published: October 2024

AbstractPurpose:
Posttreatment detection of ctDNA is strongly predictive of recurrence. Most minimal/molecular residual disease assays require prior tissue testing to guide ctDNA analysis, resulting in lengthy time to initial results and unevaluable patients.
Experimental Design:
We assessed a tissue-free assay (Guardant Reveal) that bioinformatically evaluates >20,000 epigenomic regions for ctDNA detection in 1,977 longitudinally collected postoperative plasma samples from 342 patients with resected colorectal cancer.
Results:
We observed sensitive and specific detection of minimal/molecular residual disease associated with clinically meaningful differences in recurrence-free intervals at each time point evaluated with a median lead time of 5.3 months. The longitudinal sensitivity in stage II or higher colon cancer was 81%. Sensitivity increased with serial measurement and varied by recurrence site: higher for liver (100%) versus lung (53%) and peritoneal (40%). Sensitivity among patients with rectal cancer was 60% owing to a high proportion of lung metastases. Specificity was 98.2% among 1,461 posttreatment samples (99.1% among those with follow-up longer than the upper IQR of the lead time observed in this study).
Conclusions:
Our data demonstrate the potential clinical utility of ctDNA as a tool to improve the management of stage II and higher colorectal cancer with a methodology that is noninvasive, accessible, and allows for rapid evaluation to inform clinical decisions.
Supplementary Methods from Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Authors: Tabariès Sébastien , Robert Alma , Marcil Anne , Ling Binbing , Acchione Mauro , Lippens Julie , Pagé Martine , Fortin Annie , Meury Luc , Coutu Mathieu , Annis Matthew G. , Girondel Charlotte , Navarre Julie , Jaramillo Maria , Moraitis Anna N. , Siegel Peter M.
Published: October 2024

Supplementary Methods
Supplementary Methods from Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Authors: Tabariès Sébastien , Robert Alma , Marcil Anne , Ling Binbing , Acchione Mauro , Lippens Julie , Pagé Martine , Fortin Annie , Meury Luc , Coutu Mathieu , Annis Matthew G. , Girondel Charlotte , Navarre Julie , Jaramillo Maria , Moraitis Anna N. , Siegel Peter M.
Published: October 2024

Supplementary Methods - word editable file
Supplementary Figure S6 from Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Authors: Tabariès Sébastien , Robert Alma , Marcil Anne , Ling Binbing , Acchione Mauro , Lippens Julie , Pagé Martine , Fortin Annie , Meury Luc , Coutu Mathieu , Annis Matthew G. , Girondel Charlotte , Navarre Julie , Jaramillo Maria , Moraitis Anna N. , Siegel Peter M.
Published: October 2024

Supplementary Figure S6
Supplementary Figure S5 from Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Authors: Tabariès Sébastien , Robert Alma , Marcil Anne , Ling Binbing , Acchione Mauro , Lippens Julie , Pagé Martine , Fortin Annie , Meury Luc , Coutu Mathieu , Annis Matthew G. , Girondel Charlotte , Navarre Julie , Jaramillo Maria , Moraitis Anna N. , Siegel Peter M.
Published: October 2024

Supplementary Figure S5
Supplementary Figure S2 from Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Authors: Tabariès Sébastien , Robert Alma , Marcil Anne , Ling Binbing , Acchione Mauro , Lippens Julie , Pagé Martine , Fortin Annie , Meury Luc , Coutu Mathieu , Annis Matthew G. , Girondel Charlotte , Navarre Julie , Jaramillo Maria , Moraitis Anna N. , Siegel Peter M.
Published: October 2024

Supplementary Figure S2
Supplementary Figure Legends from Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis
Authors: Tabariès Sébastien , Robert Alma , Marcil Anne , Ling Binbing , Acchione Mauro , Lippens Julie , Pagé Martine , Fortin Annie , Meury Luc , Coutu Mathieu , Annis Matthew G. , Girondel Charlotte , Navarre Julie , Jaramillo Maria , Moraitis Anna N. , Siegel Peter M.
Published: October 2024

Supplementary Figure Legends - word editable file
Figure S5 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
Authors: Anderson Amy E. , Parashar Kaustubh , Jin Ke , Clor Julie , Stagnaro Carlo E. , Vani Urvi , Singh Jaskirat , Chen Ada , Guan Yihong , Talukdar Priyanka , Sathishkumar Pavithra , Juat Damie J. , Singh Hema , Kushwaha Ritu , Zhao Xiaoning , Kaplan Angelo , Seitz Lisa , Walters Matthew J. , Fernandez-Salas Ester , Walker Nigel P.C. , Bowman Christine E.
Published: October 2024

Figure S5
Figure S1 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
Authors: Anderson Amy E. , Parashar Kaustubh , Jin Ke , Clor Julie , Stagnaro Carlo E. , Vani Urvi , Singh Jaskirat , Chen Ada , Guan Yihong , Talukdar Priyanka , Sathishkumar Pavithra , Juat Damie J. , Singh Hema , Kushwaha Ritu , Zhao Xiaoning , Kaplan Angelo , Seitz Lisa , Walters Matthew J. , Fernandez-Salas Ester , Walker Nigel P.C. , Bowman Christine E.
Published: October 2024

Figure S1
Table. S3 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
Authors: Guo Qingsong , Gao Bei , Song Ruiwen , Li Weinan , Zhu Shulei , Xie Qian , Lou Sensen , Wang Lei , Shen Jiafei , Zhao Teng , Zhang Yifan , Wu Jinsong , Lu Wei , Yang Tong
Published: October 2024

Supplementary Table. S3
Figure S4 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
Authors: Guo Qingsong , Gao Bei , Song Ruiwen , Li Weinan , Zhu Shulei , Xie Qian , Lou Sensen , Wang Lei , Shen Jiafei , Zhao Teng , Zhang Yifan , Wu Jinsong , Lu Wei , Yang Tong
Published: October 2024

Supplementary Fig.S4
Table S1 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Authors: Chen Anran , Kim Beom-Jun , Mitra Aparna , Vollert Craig T. , Lei Jonathan T. , Fandino Diana , Anurag Meenakshi , Holt Matthew V. , Gou Xuxu , Pilcher Jacob B. , Goetz Matthew P. , Northfelt Donald W. , Hilsenbeck Susan G. , Marshall C. Gary , Hyer Marc L. , Papp Robert , Yin Shou-Yun , De Angelis Carmine , Schiff Rachel , Fuqua Suzanne A.W. , Ma Cynthia X. , Foulds Charles E. , Ellis Matthew J.
Published: October 2024

KIPA-SureQuant in T47D parental and palbociclib-resistant cells
Figure S9 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Authors: Chen Anran , Kim Beom-Jun , Mitra Aparna , Vollert Craig T. , Lei Jonathan T. , Fandino Diana , Anurag Meenakshi , Holt Matthew V. , Gou Xuxu , Pilcher Jacob B. , Goetz Matthew P. , Northfelt Donald W. , Hilsenbeck Susan G. , Marshall C. Gary , Hyer Marc L. , Papp Robert , Yin Shou-Yun , De Angelis Carmine , Schiff Rachel , Fuqua Suzanne A.W. , Ma Cynthia X. , Foulds Charles E. , Ellis Matthew J.
Published: October 2024

WEE1 mRNA levels in relationship to anastrozole and palbociclib response
Figure S8 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Authors: Chen Anran , Kim Beom-Jun , Mitra Aparna , Vollert Craig T. , Lei Jonathan T. , Fandino Diana , Anurag Meenakshi , Holt Matthew V. , Gou Xuxu , Pilcher Jacob B. , Goetz Matthew P. , Northfelt Donald W. , Hilsenbeck Susan G. , Marshall C. Gary , Hyer Marc L. , Papp Robert , Yin Shou-Yun , De Angelis Carmine , Schiff Rachel , Fuqua Suzanne A.W. , Ma Cynthia X. , Foulds Charles E. , Ellis Matthew J.
Published: October 2024

Potential mechanisms of palbociclib resistance in T47D and MCF7 EDR Palbo-R cell lines
Figure S5 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Authors: Chen Anran , Kim Beom-Jun , Mitra Aparna , Vollert Craig T. , Lei Jonathan T. , Fandino Diana , Anurag Meenakshi , Holt Matthew V. , Gou Xuxu , Pilcher Jacob B. , Goetz Matthew P. , Northfelt Donald W. , Hilsenbeck Susan G. , Marshall C. Gary , Hyer Marc L. , Papp Robert , Yin Shou-Yun , De Angelis Carmine , Schiff Rachel , Fuqua Suzanne A.W. , Ma Cynthia X. , Foulds Charles E. , Ellis Matthew J.
Published: October 2024

WEE1 mRNA levels in relationship to patient outcome and endocrine therapy response
Figure S17 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Authors: Chen Anran , Kim Beom-Jun , Mitra Aparna , Vollert Craig T. , Lei Jonathan T. , Fandino Diana , Anurag Meenakshi , Holt Matthew V. , Gou Xuxu , Pilcher Jacob B. , Goetz Matthew P. , Northfelt Donald W. , Hilsenbeck Susan G. , Marshall C. Gary , Hyer Marc L. , Papp Robert , Yin Shou-Yun , De Angelis Carmine , Schiff Rachel , Fuqua Suzanne A.W. , Ma Cynthia X. , Foulds Charles E. , Ellis Matthew J.
Published: October 2024

Representative images of T47D Palbo-R with dead cells labeled in green color
Supplementary Figure S8 from Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment
Authors: Chen Chang-Jung , Wang Hao-Chen , Hou Ya-Chin , Wu Yi-Ying , Shieh Chi-Chang , Shan Yan-Shen
Published: October 2024

Supplementary Figure S8. Blocking STAT6 and HDAC2 can prevent M2 polarization, maintain M1 polarization, and restore CYBB expression in U937 cells after IL-4 treatment. A, and B, Western blotting analysis for STAT6 and HDAC2 expression in shSTAT6 and shHDAC2 U937 cells after treatment with IL-4 for 1h was performed. C, D, and E, RT-qPCR analysis for M1/M2 markers and CYBB mRNA expression was performed in shSTAT6 and shHDAC2 U937 cells treated with IL-4 for 1h. The bar graphs depict relative mRNA expression. *, p < 0.05; ***, p < 0.001, significant differences between groups. Data represent the mean of 3 independent experiments.
Supplementary Figure S14 from Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment
Authors: Chen Chang-Jung , Wang Hao-Chen , Hou Ya-Chin , Wu Yi-Ying , Shieh Chi-Chang , Shan Yan-Shen
Published: October 2024

Supplementary Figure S14. The expression of Granzyme B is significantly increased in mouse pancreatic tumors treated with STAT6-CYBB ODN. A, IHC staining for the cytotoxic marker Granzyme B was performed in KPC tumors from the scrambled ODN, mutated ODN, and STAT6-CYBB ODN-treated mice. B, The bar graph depicts the average numbers of granzyme B positive cells per field. ***, p < 0.001, compared to the scrambled ODN treatment group. Five random fields of 3 random sections from each mouse were used to quantify the positive cells
Table S4 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer
Authors: Nouri Mannan , Varkaris Andreas , Ridinger Maya , Dalrymple Susan L. , Dennehy Christopher M. , Isaacs John T. , Einstein David J. , Brennen W.N. , Balk Steven P.
Published: October 2024

Table S4 (z-score < -3 hits)
Supplementary Figure S10 from Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment
Authors: Chen Chang-Jung , Wang Hao-Chen , Hou Ya-Chin , Wu Yi-Ying , Shieh Chi-Chang , Shan Yan-Shen
Published: October 2024

Supplementary Figure S10. JAK/STAT6/HDAC2 is the downstream signaling in regulating CYBB expression in THP-1 cells. A, RT-qPCR analysis for IL-4 expression was performed in THP-1 cells co-cultured with different pancreatic cell lines. The bar graphs depict relative mRNA expression. ***, p < 0.001, significant differences between groups. Data represent the mean of 3 independent experiments. B, RT-qPCR analysis for CD86 and MSR1(CD204) expression was performed in THP-1 cells co-cultured with different pancreatic cell lines. The bar graphs depict relative mRNA expression. ***, p < 0.001, significant differences between groups. Data represent the mean of 3 independent experiments. C, THP-1 cells were cocultured with PANC-1 cells and simultaneously treated with IL-4 neutralizing antibodies. After 72 h of incubation, THP-1 cells were collected for Western blotting to measure M1/M2 markers, CYBB, and GAPDH protein expression. D, Time-dependent effect of IL-4 (20 ng/mL) on CD86, CD204, CD206 (MRC1), STAT6, HDAC2, and CYBB protein expression was determined by Western blotting. E, THP-1 cells were pre-treated with the JAK1 inhibitor (Ruxolitinib, 10 μM), the JAK3 inhibitor (Tofacitinib, 50 μM), the STAT6 inhibitor (AS1517499, 250 nM), and the HDAC inhibitor (TSA, 10 uM) for 24h and then were treated with IL-4 (20 ng/mL) for 1h. Cell lysates were collected for Western blot analysis to measure indicated protein expression.
Figure S5 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer
Authors: Nouri Mannan , Varkaris Andreas , Ridinger Maya , Dalrymple Susan L. , Dennehy Christopher M. , Isaacs John T. , Einstein David J. , Brennen W.N. , Balk Steven P.
Published: October 2024

Selected hits from primary drug screen.
Supplemental Figure S1 from Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
Authors: Parker Gregory S. , Toth Julia I. , Fish Sarah , Blanco Gabrielle , Kampert Taylor , Li Xiaoming , Yang Linette , Stumpf Craig R. , Steadman Kenneth , Jamborcic Aleksandar , Chien Stephen , Daniele Elizabeth , Dearie Alejandro , Leriche Geoffray , Bailey Simon , Thompson Peggy A.
Published: October 2024

Supplemental Figure S1 shows BRD4 degradation kinetics in the HiBiT reporter cell line
Supplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Authors: Sudhakar Niranjan , Yan Larry , Qiryaqos Fadia , Engstrom Lars D. , Laguer Jade , Calinisan Andrew , Hebbert Allan , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Ketcham John M. , Ivetac Anthony , Smith Christopher R. , Lawson J. David , Rahbaek Lisa , Clarine Jeffrey , Nguyen Natalie , Saechao Barbara , Parker Cody , Elliott Adam J. , Vanderpool Darin , He Leo , Hover Laura D. , Fernandez-Banet Julio , Coma Silvia , Pachter Jonathan A. , Hallin Jill , Marx Matthew A. , Briere David M. , Christensen James G. , Olson Peter , Haling Jacob , Khare Shilpi
Published: October 2024

Supplementary Table S1 details the efficacy of MRTX0902 in a panel of cancer cell lines.
Supplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Authors: Sudhakar Niranjan , Yan Larry , Qiryaqos Fadia , Engstrom Lars D. , Laguer Jade , Calinisan Andrew , Hebbert Allan , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Ketcham John M. , Ivetac Anthony , Smith Christopher R. , Lawson J. David , Rahbaek Lisa , Clarine Jeffrey , Nguyen Natalie , Saechao Barbara , Parker Cody , Elliott Adam J. , Vanderpool Darin , He Leo , Hover Laura D. , Fernandez-Banet Julio , Coma Silvia , Pachter Jonathan A. , Hallin Jill , Marx Matthew A. , Briere David M. , Christensen James G. , Olson Peter , Haling Jacob , Khare Shilpi
Published: October 2024

Supplementary Figure S1 details the genetic vulnerabilities and modifiers of response associated with combination treatment of MRTX0902 with adagrasib in the KRAS G12C-mutant MIA PaCa-2 (S1A, S1B, S1D, and S1E) and LU99 (S1C) cell lines in vitro and in vivo.
Supplementary Table S1 from Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia
Authors: Strickland Lincoln N. , Liu Wendao , Hussein Usama , Mardik Nicolette , Chen Xian , Mills Tingting , Vornik Lana A. , Savage Michelle I. , Sei Shizuko , Clifford John , Eltzschig Holger K. , Brown Powel H. , Zhao Zhongming , McAllister Florencia , Bailey-Lundberg Jennifer M.
Published: October 2024

Supplementary Table S1: Gene expression changes used to generate gene ontology.
Supplementary Figure S2 from Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia
Authors: Strickland Lincoln N. , Liu Wendao , Hussein Usama , Mardik Nicolette , Chen Xian , Mills Tingting , Vornik Lana A. , Savage Michelle I. , Sei Shizuko , Clifford John , Eltzschig Holger K. , Brown Powel H. , Zhao Zhongming , McAllister Florencia , Bailey-Lundberg Jennifer M.
Published: October 2024

Supplementary Figure S2. AB-680 treatment significantly alters the gene expression profiles of each identified cluster.
Figure S5 from Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non–Muscle Invasive Bladder Cancer
Authors: Yolmo Priyanka , Rahimi Sadaf , Chenard Stephen , Conseil Gwenaëlle , Jenkins Danielle , Sachdeva Kartik , Emon Isaac , Hamilton Jake , Xu Minqi , Rangachari Manu , Michaud Eva , Mansure Jose J. , Kassouf Wassim , Berman David M. , Siemens David R. , Koti Madhuri
Published: October 2024

Effect of transient B‐cell depletion and BBN exposure on urothelium of BBN exposed female and male mice.
Supplemental Table S9 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Authors: Liu Tianyi , Jin Dan , Le Son B. , Chen Dongjiang , Sebastian Mathew , Riva Alberto , Liu Ruixuan , Tran David D.
Published: October 2024

All antibodies used
Supplemental Table S8 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Authors: Liu Tianyi , Jin Dan , Le Son B. , Chen Dongjiang , Sebastian Mathew , Riva Alberto , Liu Ruixuan , Tran David D.
Published: October 2024

All primers for qPCRs